{
    "other_tests": [
        {
            "procedure_name": "Continuous Subcutaneous Recombinant PTH (1-34) Infusion",
            "date": "Not specified",
            "findings": "Effective in maintaining near-normal serum and urinary calcium levels; reduction in clinical events related to hypocalcemia.",
            "changes_over_time": "Significant reduction in hypocalcemic seizures and emergency hospitalizations over the first three years of treatment."
        },
        {
            "procedure_name": "Fecal Chymotrypsin Activity Test",
            "date": "Not specified",
            "findings": "Low fecal chymotrypsin activity at 3.2 U/g indicates digestive malabsorption.",
            "changes_over_time": "Not specified."
        },
        {
            "procedure_name": "Elastase Level Test",
            "date": "Not specified",
            "findings": "Low elastase level at 49 Âµg/g indicates digestive malabsorption.",
            "changes_over_time": "Not specified."
        },
        {
            "procedure_name": "Bone Mineral Density Measurement",
            "date": "18 months after starting CSPI",
            "findings": "P1 had a Z-score of -1.5 SD and P2 had a Z-score of -1 SD.",
            "changes_over_time": "Not specified."
        },
        {
            "procedure_name": "Bone Mineral Density Measurement",
            "date": "24 months after starting CSPI",
            "findings": "P3 had a Z-score of -0.8 SD.",
            "changes_over_time": "Not specified."
        }
    ]
}